With Jetrea being a disappointment on the commercial front, the Belgian biotech will hope that a new name will augur well for its pipeline of disease modifying compounds for diabetic eye disease.
ThromboGenics NV is dipping into Greek mythology and planning to change its name to Oxurion, a move that CEO Patrik De Haes claims is "designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders."
The Belgian biotech said in a statement that the new name, which is subject to shareholder approval and will become...
Create an account to read this article
Already a subscriber?
New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
